| __timestamp | Viridian Therapeutics, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 293000 | 15411924 |
| Thursday, January 1, 2015 | 1002000 | 22593274 |
| Friday, January 1, 2016 | 888000 | 33173050 |
| Sunday, January 1, 2017 | 19623000 | 62224159 |
| Monday, January 1, 2018 | 30421000 | 95607434 |
| Tuesday, January 1, 2019 | 34794000 | 221269028 |
| Wednesday, January 1, 2020 | 28304000 | 400745069 |
| Friday, January 1, 2021 | 56886000 | 580520000 |
| Saturday, January 1, 2022 | 100894000 | 663366000 |
| Sunday, January 1, 2023 | 159765000 | 755113687 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, argenx SE and Viridian Therapeutics, Inc. have been at the forefront of this race. Since 2014, argenx SE has consistently outpaced Viridian in R&D investment, with a staggering 4,800% increase by 2023. In contrast, Viridian's R&D spending grew by approximately 54,000% over the same period, albeit from a much smaller base.
By 2023, argenx SE's R&D expenses reached nearly 755 million, a testament to its aggressive pursuit of groundbreaking therapies. Meanwhile, Viridian's spending, though significantly lower at 160 million, reflects its strategic focus on targeted innovations. This financial commitment underscores the dynamic nature of the biotech industry, where strategic R&D investments can lead to transformative breakthroughs.
Eli Lilly and Company vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
AbbVie Inc. vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Novartis AG vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending
Regeneron Pharmaceuticals, Inc. or argenx SE: Who Invests More in Innovation?
argenx SE or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for argenx SE and Ultragenyx Pharmaceutical Inc.
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc.
Comparing Innovation Spending: Geron Corporation and Viridian Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.